Type 2 Diabetic Medication Regimen in Treating Depression and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Veterans Using PHQ-9 and FIB-4 Scores

被引：0
|
作者：
Ubalde, Shannen Nicole
Khoury, Jessica
Davis, Jessica
Sen, Sabyasachi
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1889-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1889-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A dual threat to cardiac dysfunction progression
    Wang, Wei
    Cooper, Charlie
    WORLD JOURNAL OF CARDIOLOGY, 2025, 17 (01):
  • [32] Predictors of advanced liver fibrosis and the performance of fibrosis scores: lean compared to non-lean metabolic dysfunction-associated steatotic liver disease (MASLD) patients
    Dabbah, Shoham
    Ben Yakov, Gil
    Kaufmann, Monika-Inda
    Cohen-Ezra, Oranit
    Likhter, Maria
    Davidov, Yana
    Ben Ari, Ziv
    MINERVA GASTROENTEROLOGY, 2024, 70 (03): : 322 - 331
  • [33] DO WE NEED A NEW CUT-OFF FOR FIB-4 IN THE METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE ERA?
    Ahn, Sang Bong
    Park, Huiyul
    Yoon, Eileen
    Jun, Dae Won
    An, Ji Hyun
    Sohn, Joo Hyun
    Kim, Mimi
    Kang, Bo-Kyeong
    Lee, Chul-Min
    HEPATOLOGY, 2021, 74 : 1005A - 1005A
  • [34] Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure
    Oh, Rosa
    Kim, Gyuri
    Lee, Kyu-na
    Cho, So Hyun
    Kim, Ji Yoon
    Kim, Seohyun
    Lee, You-Bin
    Jin, Sang-Man
    Hur, Kyu Yeon
    Han, Kyungdo
    Kim, Jae Hyeon
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [35] 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes
    Godoy-Matos, Amelio F.
    Valerio, Cynthia Melissa
    Silva Junior, Wellington S.
    de Araujo-Neto, Joao Marcello
    Bertoluci, Marcello Casaccia
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
  • [36] Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population
    Chew, Nicholas W. S.
    Pan, Xin Hui
    Chong, Bryan
    Chandramouli, Chanchal
    Muthiah, Mark
    Lam, Carolyn S. P.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 211
  • [37] Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
    Park, Huiyul
    Yoon, Eileen L.
    Cho, Seon
    Nah, Eun-Hee
    Jun, Dae Won
    JOURNAL OF HEPATOLOGY, 2021, 75 (03) : 725 - 726
  • [38] Effect of Lobeglitazone, a Novel Thiazolidinedione, on Liver Fat in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-A Randomized Controlled Trial (Lobe-MASLD Trial)
    Gadve, Sharvil S.
    Gadve, Sneha S.
    Gadve, Shriya
    Chavanda, Ketki S.
    Hanamshetti, Satish
    DIABETES, 2024, 73
  • [39] Agile 3+and Agile 4 scores predict chronic kidney disease development in metabolic dysfunction-associated steatotic liver disease
    Jung, Chan-Young
    Lee, Jung Il
    Ahn, Sang Hoon
    Kim, Seung Up
    Kim, Beom Seok
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (08) : 1051 - 1061
  • [40] The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Review
    Kaur, Manpreet
    Murugesan, Shanmathi
    Singh, Sachpreet
    Uy, Katherine N.
    Kaur, Jasjeet
    Mann, Navina
    Sekhon, Rajneet K.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (12)
12345